No Data
Wedbush Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $17
Wedbush analyst Laura Chico maintains $Stoke Therapeutics(STOK.US)$ with a buy rating, and maintains the target price at $17.According to TipRanks data, the analyst has a success rate of 48.0% and a
Stoke Therapeutics Price Target Maintained With a $17.00/Share by Wedbush
Wedbush Reiterates Outperform on Stoke Therapeutics, Maintains $17 Price Target
Stoke Therapeutics (STOK) Receives a Buy From Wedbush
Stoke Therapeutics(STOK.US) Officer Sells US$137.46K in Common Stock
$Stoke Therapeutics(STOK.US)$ Officer Ticho Barry sold 10,000 shares of common stock on Jul 1, 2024 at an average price of $13.7458 for a total value of $137.46K.Source: Announcement What is statement
Stoke Therapeutics(STOK.US) Officer Sells US$32,778.87 in Common Stock
$Stoke Therapeutics(STOK.US)$ Officer Nash Huw M. sold 2,500 shares of common stock on Jul 2, 2024 at an average price of $13.112 for a total value of $32,778.87.Source: Announcement What is statement
No Data